Announcement on Convening the 2025 Annual Performance Briefing
Filed with SSE · · 3 pages · Chinese
Tianjin Tianyao Pharmaceuticals Co., Ltd. on 6ix
Earlier from Tianjin Tianyao Pharmaceuticals
- Announcement on Obtaining Drug Registration Certificate by Subsidiary
- Indicative Announcement on Shanghai Industrial Investment (Holdings) Co., Ltd. and Shanghai Industrial Investment Development Co., Ltd.'s Proposed Public Solicitation of a Transferee for 100% Equity Interest in Shanghai Liuliguang Pharmaceutical Development Co., Ltd.
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on the 2025 Evaluation Report on ""Corporate Value and Return Enhancement"" and 2026 Action Plan
Later from Tianjin Tianyao Pharmaceuticals
- Announcement on Resolutions of the 27th Meeting of the 9th Board of Directors
- Announcement on the Subsidiary's Drug Passing Consistency Evaluation of Generic Drug
- Announcement on Obtaining Drug Registration Certificate for Its Methylprednisolone Tablets from the Ministry of Health of the Republic of Belarus
- Announcement on Obtaining FDA DMF First Adequate Letter for Betamethasone Dipropionate API
- Announcement on Implementation of Dividend Distribution for 2025
Follow Tianjin Tianyao Pharmaceuticals into a list and get an email when it puts out news.
Follow Tianjin Tianyao Pharmaceuticals